Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: October 2007

Intervention(s) in this Clinical Trial

• Drug: bimatoprost 0.03% eye drops
  • bimatoprost 0.03% 1 drop nightly for 3 months
• Drug: travaprost 0.004% eye drops
  • travaprost 0.004% 1 drop nightly for 3 months

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
• Active Comparator: 2

Primary Measures

• IOP
  • Time Frame: Month 3
    Safety Issue?: No

Secondary Measures

• Tolerability
  • Time Frame: Month 3
    Safety Issue?: No

Inclusion Criteria:

• Glaucoma or ocular hypertension in both eyes
• Currently being treated with latanoprost 0.005% daily and in need of additional
• IOP-lowering
• Best-corrected visual acuity of 20/100 or better in each eye
• Visual filed within 6 months of study entry

Exclusion Criteria:

• Secondary glaucoma
• Active intraocular inflammation or macular edema
• Intraocular surgery or laser surgery within the past 3 months

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Allergan

Overall Clinical Trial Officials and Contacts

Medical Affairs Study Director Allergan  

Information obtained from ClinicalTrials.gov on August 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00440011

Study ID Number: MA-LUM01

ClinicalTrials.gov Identifier: NCT00440011

Health Authority: United States: Institutional Review Board